Xenon Pharmaceuticals Surges 49.6% After Trial Shows 53.2% Seizure Drop
Xenon Pharmaceuticals shares jumped 49.6% to $62.76 after its Phase 3 X-TOLE2 trial of azetukalner delivered a 53.2% reduction in focal onset seizure frequency versus placebo. With $716 million cash runway into H2 2027 and an average $56.50 price target from 21 analysts, NDA submission is planned in H2 2026.
1. Phase 3 X-TOLE2 Trial Success
Xenon’s X-TOLE2 Phase 3 trial of azetukalner achieved a 53.2% reduction in focal onset seizure frequency versus placebo, with open-label data showing over 90% monthly reduction and 38% of patients seizure-free for 12 months.
2. Strong Cash Position and Analyst Ratings
The company holds $716 million in pro forma cash, funding operations into the second half of 2027, while a consensus of 21 analysts maintain Buy or Strong Buy ratings with an average $56.50 price target, reflecting raised outlooks after the trial readout.
3. Next Steps Toward FDA Approval
Xenon plans to submit a New Drug Application for azetukalner in the second half of 2026 and maintains five active Phase 3 studies across epilepsy and neuropsychiatry, creating multiple late-stage catalysts over the coming two years.